Anthem Biosciences IPO
Anthem Biosciences IPO open date is July 14, 2025 and the IPO will close on July 16, 2025. Anthem Biosciences IPO is a Book Build Issue. The company to raise around ₹3,395 crores ...
Anthem Biosciences IPO price band is ₹540 to ₹570 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Anthem Biosciences IPO to list on BSE, NSE on July 21, 2025. The allotment of Anthem Biosciences IPO date is July 17, 2025.
The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crore in 2024. The company reported profit of ₹451.26 crores in 2025 against profit of ₹367.31 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.
Read moreIPO Timeline
-
14 Jul 2025Bidding Starts
-
16 Jul 2025Bidding Ends
-
17 Jul 2025Allotment Finalization
-
18 Jul 2025Refund Date
-
18 Jul 2025Demat Date
-
21 Jul 2025Listing Date
Anthem Biosciences IPO Financial Result in crore
| Year | Asset | Revenue | Profit |
|---|---|---|---|
| Mar 2023 | 2,014.46 Cr | 1,133.99 Cr | 385.19 Cr |
| Mar 2024 | 2,398.11 Cr | 1,483.07 Cr | 367.31 Cr |
| Mar 2025 | 2,807.58 Cr | 1,930.29 Cr | 451.26 Cr |
About Anthem Biosciences IPO
About Anthem Biosciences IPO
Anthem Biosciences Limited, founded in 2006, is one of the growing innovation-driven and technology-focused Contract Research, Development and Manuf
...
Anthem Biosciences is a one-stop service provider engaged in serving a wide range of customers, including emerging biotech companies and large pharmaceutical firms around the world. The company is involved in the manufacturing of specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company has supplied to over 150 customers, from small biotech to large pharmaceutical companies, as of March 31, 2024. Currently, the company has a team of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, and chemical engineers.
Strengths:
- Established Market Position: Anthem Biosciences is one of India's fastest-growing Contract Research, Development and Manufacturing Organizations (CRDMO).
- Strong Financial Performance: The company reported a 30% increase in revenue (₹1,930.29 crores in 2025 vs ₹1,483.07 crore in 2024) and a 23% rise in profit (₹451.26 crores in 2025 vs ₹367.31 crore in 2024).
- Comprehensive Service Portfolio: Anthem offers end-to-end CRDMO services across small and large molecules (New Chemical Entities (NCE) and New Biological Entities (NBE)).
- Focus on Innovation and Technology: The company has expertise in advanced modalities like RNAi, ADCs, peptides, lipids, and oligonucleotides.
- Specialized Business Model: Anthem caters to small pharmaceutical and biotech companies, offering cost-effective and quality services through a Fee-for-Service (FFS) model.
Global Customer Base: It serves over 550 clients across 44 countries, including regulated markets like the US, Europe, and Japan.
Risks:
- Dependence on CRDMO Services and Manufacturing: A significant portion of revenue comes from CRDMO services (81.13% in H1 FY25) and developmental/commercial manufacturing (73.06% in H1 FY25), making the company vulnerable to downturns in these segments.
- Customer Concentration: The top five and top ten customers contributed a substantial portion of revenue (69.86% and 76.75% respectively in H1 FY25), increasing revenue volatility.
- Regulatory Risks: The company operates in a highly regulated industry and is subject to stringent quality and compliance norms, with regulatory approvals and inspections impacting operations.
Competitive Industry: The CRAMS industry is competitive, with large and established players.
Read more
Objects of the Issue
The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.
Promoters of Anthem Biosciences IPO
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.
FAQs
What is Anthem Biosciences IPO?
Anthem Biosciences IPO is a Mainboard IPO. The company is going to raise ₹3,395 Crores via IPO. The issue is priced at ₹540 to₹570 per equity share. The IPO is to be listed on BSE & NSE.
When Anthem Biosciences IPO will open for subscription?
The IPO is to open on July 14, 2025 for QIB, NII, and Retail Investors. The IPO will close on July 16, 2025.
What is Anthem Biosciences IPO Investors Portion?
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
What is Anthem Biosciences IPO Issue Size?
Anthem Biosciences IPO issue size is ₹3,395 crores.
What is Anthem Biosciences IPO Price Band?
Anthem Biosciences IPO Price Band is ₹540 to₹570.
What is Anthem Biosciences IPO Lot Size?
The minimum bid is 26 Shares with ₹14,820 amount.
What is the Anthem Biosciences IPO Listing Date?
Anthem Biosciences IPO listing date is July 21, 2025. The IPO is to list on BSE & NSE.
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, InvestExpert Academy does not take any liability for the genuineness and correctness of the information in this article.